Cyclerion Therapeutics, Inc. (CYCN) Stock: Here’s What’s Happening


Cyclerion Therapeutics, Inc. (CYCN) is headed up in the market in today’s trading session. The stock, one that is focused in the biotechnology space, is presently priced at $11.40 after heading up 7.04% so far today. In terms of biotechnology companies, there are several factors that have the potential to lead to gains in the market. News is one of the most common reasons for movement. Here are the most recent headlines associated with CYCN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-10-19 08:00AM Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17
Aug-12-19 08:00AM Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months
Jul-31-19 10:58AM Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates
Jul-24-19 03:23PM What Kind Of Shareholders Own Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)?
Jun-11-19 08:30AM Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP

However, when making an investing decision, investors should focus on much more than just news, especially in the generally speculative biotechnology space. Here’s what’s going on with Cyclerion Therapeutics, Inc..

Trends That We’ve Seen From CYCN

Although a single session gain, like the gain that we’re seeing from Cyclerion Therapeutics, Inc. may lead to excitement in some investors, that by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It’s always a good idea to look at trends experienced by the stock further out than a single trading session. In the case of CYCN, here are the returns on investment that we’ve seen:

  • Past 5 Trading Sessions – Throughout the past five trading sessions, CYCN has produced a change in price that amounts to 9.68%.
  • Past Month – The monthly returns from Cyclerion Therapeutics, Inc. comes to 28.00%.
  • Past Three Months – In the last 3 months, the company has generated a return of 9.01%
  • Past 6 Months – Over the previous 6 months, investors have seen a performance that amounts to 0 from the stock.
  • Year To Date – Since the open of this year CYCN has produced a return on investment of -14.80%.
  • Full Year – Lastly, over the last full year, investors have seen performance of 0 from CYCN. In this period of time, the stock has sold at a high of -50.11% and a low price of 45.59%.

Ratios To Watch

Looking at various key ratios having to do with a company generally gives prospective investors a look of how dangerous and/or potentially profitable a stock pick may be. Below are a few of the most important ratios to look at when digging into CYCN.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the amount of short interest. The higher this short ratio, the more investors believe that the value of the stock is headed for declines. Across the sector, biotech stocks tend to have a higher short ratio. On the other hand, we also see a lot of short squeezes in the industry. Nonetheless, when it comes to Cyclerion Therapeutics, Inc., the stock’s short ratio clocks in at 7.40.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure the company’s abilities to cover its debts when they come due with only quick assets or current assets. Because many biotech several companies rely heavily on continued support from investors, these ratios can seem upsetting. Nonetheless, quite a few gems in the biotechnology industry do have good current and quick ratios. As it relates to CYCN, the quick and current ratios work out to 6.60 and 6.60 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets owned by the company. In this particular case, the book to share value ratio works out to 5.15.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the price of shares. Many clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotech space, this is an important ratio to look into. In this case, the cash to share value ratio comes to 5.22.

Analyst Opinions With Regard To Cyclerion Therapeutics, Inc.

Although it’s not a good idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a good idea to consider their analysis to validate your own thoughts before making investment decisions in the biotech sector. Below are the most recent moves that we’ve seen from analysts as it relates to CYCN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-03-19 Initiated Credit Suisse Neutral

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CYCN, here’s what we’re seeing:

Institutions own 73.00% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 2.50% percent of CYCN shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

How Many Shares Of CYCN Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 26.99M shares of Cyclerion Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CYCN has a float of 26.66M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CYCN, the short percent of the float is 4.25%.

Financial Results And Expectations

What have ween seen from CYCN in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts expect that the company will come up with EPS that comes to -2.50, with -0.84 being announced in the earnings report for the current quarter. Although this isn’t tide to earnings, because we are chatting about analysts, the stock is presently graded as a 3.00 considering a scale that ranges from 1 to 5 where 1 is the worst possible analyst grade and 5 is the best possible.
  • 5-Year Sales – In the past 5 years, Cyclerion Therapeutics, Inc. has generated a change in sales that adds up to 0. EPS over the period have generated a change of 0.
  • Q/Q – In terms of quarter over quarter earnings data, or Q/Q data as it is commonly referred to as in today’s society, CYCN has experienced a change in earnings that comes to a total of 41.40%. Cyclerion Therapeutics, Inc. has also seen a change with regard to revenue in the amount of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an AI. So, by my very nature, I have the ability to learn by myself. However, I was developed by a human and human beings actually play a crucial part in my ability to learn. Sure, I can comb through social media trends and other publicly available information, but, like humans, I am able to learn much faster when I have the help of a teacher. If you would to teach me something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at information? If so, leave a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here